ZYXI logo

Zynex, Inc. Stock Price

NasdaqGS:ZYXI Community·US$5.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 27 Fair Values set on narratives written by author

ZYXI Share Price Performance

US$0.13
-7.95 (-98.45%)
US$3.70
Fair Value
US$0.13
-7.95 (-98.45%)
96.6% undervalued intrinsic discount
US$3.70
Fair Value
Price US$0.13
AnalystConsensusTarget US$3.70
AnalystHighTarget US$3.70
AnalystLowTarget US$2.00

ZYXI Community Narratives

AnalystConsensusTarget·
Fair Value US$3.7 96.6% undervalued intrinsic discount

Aging Populations And FDA Moves Will Unlock New Markets

0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
AnalystHighTarget·
Fair Value US$3.7 96.6% undervalued intrinsic discount

Telehealth And Home Healthcare Will Redefine Pain Management

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value US$2 93.8% undervalued intrinsic discount

Regulatory And Reimbursement Issues Will Limit Revenue While Operations Stabilize

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$3.7
96.6% undervalued intrinsic discount
Revenue
7.57% p.a.
Profit Margin
12.91%
Future PE
7.88x
Price in 2028
US$5.22
US$3.7
96.6% undervalued intrinsic discount
Revenue
-3.86% p.a.
Profit Margin
0.56%
Future PE
183.23x
Price in 2028
US$5.03
US$2
93.8% undervalued intrinsic discount
Revenue
-8.42% p.a.
Profit Margin
12.32%
Future PE
5.17x
Price in 2028
US$2.72

Trending Discussion

Updated Narratives

ZYXI logo

ZYXI: Forward Earnings Multiple Will Drive Bullish Opportunity Despite Filing Delay

Fair Value: US$3.7 96.6% undervalued intrinsic discount
19 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ZYXI logo

Regulatory And Reimbursement Issues Will Limit Revenue While Operations Stabilize

Fair Value: US$2 93.8% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ZYXI logo

Telehealth And Home Healthcare Will Redefine Pain Management

Fair Value: US$3.7 96.6% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Slight risk and fair value.

4 Risks
1 Reward

Zynex, Inc. Key Details

US$108.2m

Revenue

US$30.3m

Cost of Revenue

US$77.9m

Gross Profit

US$151.9m

Other Expenses

-US$74.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-2.43
72.01%
-68.35%
-143.4%
View Full Analysis

About ZYXI

Founded
1996
Employees
1000
CEO
Steven Dyson
WebsiteView website
www.zynex.com

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Recent ZYXI News & Updates

Recent updates

No updates